ストックスクリーナーアプリを入手
37.60
2.62%
-1.01
Sarepta Therapeutics Inc (SRPT) 最新ニュース
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent
Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg.com
July 11th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq
We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right - simplywall.st
Oppenheimer to Host Important Meeting for SRPT Investors | SRPT Stock News - GuruFocus
Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's
Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? - Insider Monkey
FDA halts Rocket Pharma's gene therapy trial as patient dies - Reuters
Was Jim Cramer Right About These 11 Stocks? - Insider Monkey
Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces growth challenges - Investing.com
Will Moderna's Rally Continue? - Forbes
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm | FinancialContent - FinancialContent
FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study - BioPharma Dive
SRPT: HC Wainwright & Co. Reiterates Neutral Rating on Sarepta Therapeutics | SRPT Stock News - GuruFocus
Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Sto - GuruFocus
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVID - GuruFocus
Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne - Yahoo Finance
Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Rallies After UK Lifts Clinical Hold on Elevidys Trials - GuruFocus
Sarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study Continue - MarketWatch
Sarepta, Roche get U.K. feedback to continue dosing in Elevidys' Duchenne trial - Seeking Alpha
Sarepta (SRPT) Gains UK Approval to Continue Gene Therapy Study - GuruFocus
Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment - marketscreener.com
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy - marketscreener.com
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | SRPT Stock News - GuruFocus
Assessing Sarepta Therapeutics: Insights From 30 Financial Analysts - Benzinga
Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | S - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | SRPT Stock News - GuruFocus
SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays - Yahoo Finance
Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy - Yahoo Finance
Sarepta reports promising ELEVIDYS study results for Duchenne By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Shares New Protein Expression and Safety Re - GuruFocus
Sarepta Therapeutics Presents Data at the American Society of Ge - GuruFocus
Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers - Endpoints News
Sarepta (SRPT) Reports Promising Results from ELEVIDYS Trial in Young Patients | SRPT Stock News - GuruFocus
Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy - GuruFocus
Sarepta Reports New Elevidys Data from Two Separate Studies in Duchenne Muscular Dystrophy - marketscreener.com
Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy | SRPT Stock News - GuruFocus
Sarepta reports promising ELEVIDYS study results for Duchenne - Investing.com Australia
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysi - GuruFocus
Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids - BioSpace
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - itemonline.com
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 - Business Wire
Nucleic Acid Therapeutics Market Trends, Size & Growth Forecast - openPR.com
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore - Yahoo Finance
Sarepta at BofA Conference: Navigating Challenges and Growth - Investing.com
Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates - Yahoo Finance
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore - MarketBeat
Sarepta Therapeutics: Hold Rating Amid Limited Financial Gains from ELEVIDYS Approval and Market Adoption Concerns - TipRanks
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):